AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Nektar Therapeutics
Video analysis: NKTR
All videosNo video analysis for this stock yet. Request one from our team.
News: NKTR
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease Findings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in The Lancet, a world-leading medical journal, provides the medical and scientific community with the full reporting of efficacy, safety, pharmacodynamics, pharmacokinetics, and biomarker findings from the 16-week induction period of the Phase 2b trial.
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028. REZPEG's differentiated mechanism aims for long-term disease control and safety advantages over current AD therapies, addressing a $37.3B global market.
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics Q2 Earnings Call Highlights
Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the U.S. Food and Drug Administration.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $2.78 per share a year ago.
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025.
